Abi Millar

All articles by Abi Millar

1. Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill

   For the past five years, ViiV Healthcare (a global specialist HIV company) has been collaborating with the University of North…
   Read More…

   1 Jun
2. Q&A: is pharma ready to address the health effects of climate change?

   While coronavirus is commanding the headlines for now, we are facing another major public health threat in terms of climate…
   Read More…

   4 May
3. Peptomyc: the quest for a ‘universal’ cancer treatment

   These days, when we talk about emerging cancer therapies, we’re mostly talking about personalised or precision medicine. In contrast to…
   Read More…

   30 Apr
4. Q&A: talking innovation with the Association for the Cannabinoid Industry

   The UK’s cannabidiol (CBD) market has exploded over the past few years, and shows no signs of slowing down. One…
   Read More…

   17 Mar
5. Sky high: should US drug prices fall in-line with the rest of the world?

   In September, US Speaker of the House Nancy Pelosi unveiled her plan to curb soaring drug prices. Called HR3, or…
   Read More…

   29 Jan
6. What does ‘ageing’ mean when it comes to drug development?

   One of the great triumphs of modern medicine is the fact that people are living longer. As of 2020, people…
   Read More…

   15 Jan
7. The rise of fake medicines in Africa

   Counterfeit drugs are a deadly, and growing, problem. According to the World Health Organization, as many as one in ten…
   Read More…

   3 Jan
8. Q&A: Gavi alliance talks immunising 300 million people

   Since Gavi, the Vaccine Alliance, was launched in 2000, it has played a major role in immunisation efforts across the…
   Read More…

   5 Dec
9. Recurrent miscarriage: could this devastating condition have a simple cure?

   For those who’ve experienced recurrent miscarriages, the devastation can be immense. While around one in five pregnancies end in miscarriage…
   Read More…

   3 Dec
10. The problem of manipulated data

    In August, Novartis came under fire for submitting manipulated data in an application to the FDA. The problem lay with…
    Read More…

    2 Dec